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Inhibiting ex-vivo Th17 responses in 
Ankylosing Spondylitis by targeting 
Janus kinases
Ariane Hammitzsch1,2, Liye Chen1, Jelle de Wit  1,4, M. Hussein Al-Mossawi  1, Anna Ridley1, 
Takuya Sekine1,5, Davide Simone1, Karen Doig1, Alla Skapenko3 & Paul Bowness1
Treatment options for Ankylosing Spondylitis (AS) are still limited. The T helper cell 17 (Th17) pathway 
has emerged as a major driver of disease pathogenesis and a good treatment target. Janus kinases 
(JAK) are key transducers of cytokine signals in Th17 cells and therefore promising targets for the 
treatment of AS. Here we investigate the therapeutic potential of four different JAK inhibitors on cells 
derived from AS patients and healthy controls, cultured in-vitro under Th17-promoting conditions. 
Levels of IL-17A, IL-17F, IL-22, GM-CSF and IFNγ were assessed by ELISA and inhibitory effects were 
investigated with Phosphoflow. JAK1/2/3 and TYK2 were silenced in CD4+ T cells with siRNA and effects 
analyzed by ELISA (IL-17A, IL-17F and IL-22), Western Blot, qPCR and Phosphoflow. In-vitro inhibition 
of CD4+ T lymphocyte production of multiple Th17 cytokines (IL-17A, IL-17F and IL-22) was achieved 
with JAK inhibitors of differing specificity, as well as by silencing of JAK1-3 and Tyk2, without impacting 
on cell viability or proliferation. Our preclinical data suggest JAK inhibitors as promising candidates 
for therapeutic trials in AS, since they can inhibit multiple Th17 cytokines simultaneously. Improved 
targeting of TYK2 or other JAK isoforms may confer tailored effects on Th17 responses in AS.
Ankylosing Spondylitis (AS) is a chronic inflammatory arthritis affecting the sacroiliac spinal and large joints, 
with a prevalence of approximately 0.25% in Europe1, ultimately causing bony ankylosis, pain and disability2. 
Treatment options have previously been limited to non-steroidal anti-inflammatory drugs and anti-TNF (tumor 
necrosis factor) biologic agents, with one third of patients not profiting from the latter3–5. Therefore alternative 
treatment options are warranted. More recently antibodies targeting the Interleukin-23/Interleukin-17 (IL-23/
IL-17) axis have shown efficacy and, together with findings from genome wide association studies (GWAS) and 
immune phenotyping data, strongly support a pivotal role for T helper cell type 17 (Th17) responses in AS patho-
genesis, and open the road for new drug targets in this pathway6–10.
Janus kinases 1/2/3 (JAK1/2/3) and Tyrosine kinase 2 (TYK2), in conjunction with signal transducers and acti-
vators of transcription (STAT), are central transmitters of pro- and anti-inflammatory cytokine signals in immune 
cells and therefore interesting targets for immunomodulation11. Other processes depending on JAK-STAT signa-
ling include erythropoiesis, myelopoiesis and platelet production via JAK2, as well as innate anti-viral responses 
via type I Interferons and Interferon γ (IFNγ)12. Tofacitinib, with specificity for JAK1 and JAK3, reduces IL-23 
triggered IL-17A secretion from T cells of rheumatoid arthritis (RA) and psoriatric arthritis (PSA) patients in 
vitro13,14, and was the first JAK inhibitor to be licensed for treatment of RA in the United States15,16. Subsequently 
Tofacitinib has also been shown to be effective in a phase II clinical trial in AS17. Nevertheless Tofacitinib is far less 
selective than initially thought, especially in CD4+ T cells in-vitro18,19. Targeting specific JAK could yield selec-
tive effects and reduce adverse events, since different JAK are involved in different pro- and anti-inflammatory 
cytokine signaling cascades. IL-23 signaling, which is required for the stabilization and maintenance of Th17 
cells, is thought to be transmitted through STAT3 upon JAK2/TYK2 activation, making inhibitors for these JAK 
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family members most interesting targets for treatment of AS and other Th17-driven diseases20. In addition GWAS 
studies of AS have shown a disease association with a rare single nucleotide polymorphism (SNP) in the TYK2 
gene21. Integration of TYK2 SNP associations across different autoimmune diseases singled out rs3453644 as 
protective for AS. Homozygocity of the minor allele of this TYK2 SNP leads to reduced STAT3 phosphorylation 
upon IL-23 stimulation22.
We here demonstrate the in-vitro efficacy of JAK inhibition and silencing on Th17 responses from 
Spondyloarthritis (SPA) patients.
Results
JAK inhibitors of different specificities inhibit Th17 responses in CD4+ T cells from patients 
and healthy controls in-vitro. We first tested four JAK inhibitors of different reported specificity (see 
Supplementary Table S1) for their ability to inhibit secretion of IL-17A from purified blood CD4+ T cells cultured 
for 3 days in an initial cohort of 43 Ankylosing Spondylitis (AS), 16 Psoriatic Arthritis (PSA), 18 Rheumatoid 
Arthritis (RA) patients and 26 healthy controls (HC). Patient characteristics for the entire study cohort are 
summarized in Table 1. We studied the following inhibitors: Tofacitinib (hereafter abbreviated Tofa, reported 
inhibitory specificity JAK3 > JAK1/2), Ruxolitinib (Ruxo, JAK2 > JAK1), Baricitinib (Bari, JAK1/2 > TYK2) and 
CEP-33779 (CEP, JAK2). We additionally studied Bayer-18 (TYK2 > JAK2) but saw no consistent effects in-vitro 
in initial experiments. Therefore Bayer-18 was not investigated further. Concentrations of inhibitors were based 
on initial dose-response experiments using purified healthy control CD4+ T cells quantifying cytotoxicity and 
anti-proliferative capacity (Supplementary Fig. S1a–c). Figure 1a shows that multiple JAK inhibitors (Tofa, Ruxo, 
Bari and CEP) potently inhibited IL-17A production for inflammatory arthritis patients and controls (Original 
data are available in Supplementary Fig. S2a). No disease-specific effects were observed. In order to delineate the 
specific effect of the inhibitors on IL-23-triggered IL-17A production in AS, we tested the inhibitors on purified 
blood CD4+ T cells from AS patients in the presence of IL-2, or IL-2 + IL-23. Addition of IL-23 increased the 
production of Th17 cytokines. However, JAK-triggered inhibition of IL-17A and IL-22 secretion was greater for 
IL-2 stimulation compared to IL-2 + IL-23 stimulation, despite being significant in both conditions (p < 0.001, 
Supplementary Fig. S3a,b). Only Tofa inhibited IL-17A secretion similarly in IL-2, and IL-2 + IL-23 conditions. 
Effects on other Th17 cytokines and on IFNγ were assessed in a subgroup of AS patients and HC. Inhibition of 
IL-17F, IL-22 and IFNγ secretion was observed with multiple inhibitors, but only Tofa, Baricitinib and CEP inhib-
ited Granulocyte-Macrophage colony-stimulating factor (GM-CSF) production significantly (p < 0.001, <0.05 
and <0.001 respectively) in AS patients (Fig. 1b).
JAK inhibitors inhibit IL-17A production by established Th17 cells and by synovial fluid CD4+ 
T cells from AS/SPA patients. Addition of the inhibitors in-vitro also reduced IL-17A responses from 
established Th17 cell lines from AS patients (after 6 days of Th17-promoting conditions, Fig. 2a). Figure 2b shows 
that JAK inhibitors also effectively reduced IL-17A secretion by SPA synovial CD4+ T cells demonstrating effects 
on joint derived cells.
HC (n = 26) AS (n = 52) PSA (n = 16) RA (n = 18)
age, years (median and range) 40.1 [26;64] 41.0 [23;73] 47.9 [26;71] 53.6 [22;84]
male/female, no. 16/10 32/20 9/7 4/14
HLA-B27 positive, % na 86.7† 50.0† na
RF positive, % na na na 75.0‡
anti-CCP positive, % na na na 86.7*
BASDAI (SD) na 4.6 (2.5)+ na na
DAS28 CRP (SD) na na na 2.7 (1.3)^
CRP, mg/L (SD) na 18.4(26.9)∞ 17.1 (27.5)∞ 7.5 (9.9)∞
Treatment
anti-TNF, no. na 11/52 1/16 0/18
DMARD, no. na 10/52 13/16 18/18
Steroid, no. na 0/52 0/16 0/18
Comorbidities na na na
Uveitis, no. 13/52
Psoriasis, no. 4/52
IBD (UC/CD), no. 6/52
Table 1. Study population characteristics. HLA-B27 (human leucocyte antigen-B27), RF (rheumatoid 
factor), anti-CCP (anti-cyclic citrullinated peptide), BASDAI (Bath Ankylosing Spondylitis Disease Activity 
Index), DAS28 CRP (Disease Activity Score 28 CRP), CRP (c-reactive protein), DMARD (Disease-modifying 
antirheumatic drug), IBD (inflammatory bowel disease), UC (ulcerative colitis), CD (Crohn’s disease). †Data 
available for 44 AS and 4 PSA patients. ‡Data available for 16 RA patients. *Data available for 15 RA patients. 
+Data available for 45 AS patients. ^Data available for 14 RA patients. ∞Data available for 38 AS, 15 PSA and 17 
RA patients.
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Small molecule JAK inhibitors have broad inhibitory actions on STAT phosphorylation. We 
next analysed STAT phosphorylation in AS patient-derived PBMC upon stimulation with IL-6 (reported to signal 
through JAK1/2 – STAT1/3), Interferon α (IFNα; JAK1/TYK2 – STAT1/5), IL-7 (JAK1/3 – STAT5) and GM-CSF 
(JAK2 – STAT5), in the presence of Tofa, Ruxo, Bari and CEP (Fig. 3a–d and Supplementary Table S2). Following 
IL-6 stimulation, Tofa, Ruxo, Bari and CEP all inhibited STAT1 phosphorylation, but STAT3 phosphorylation was 
only modestly reduced by Tofa and CEP (Fig. 3a). Following IFNα stimulation signaling via STAT1 and STAT5 
Figure 1. JAK inhibitors inhibit CD4+ T cell “type 17” cytokine production in-vitro in Spondyloarthritis, 
Rheumatoid Arthritis and healthy controls. (a) IL-17A secretion from CD4+ T cells cultured under Th17-
promoting conditions in-vitro in the presence of JAK inhibitors (Tofa, JAK3 > JAK1/2; Ruxo, JAK2 > JAK1; 
Bari, JAK1/2 > TYK2; CEP, JAK2) from day 0 to 3. Measured by supernatant ELISA and normalized to DMSO 
control (=100%) on day 3 (no.s AS = 43/Bari = 10, HC = 26/Bari = 14, PSA = 16/Bari = 3 and RA = 18/
Bari = 9). (b) Inhibitory effects of JAK inhibitors on IL-17F, IL-22, GM-CSF and IFNγ secretion from AS 
(n = 10 – 8 – 9 – 6 respectively) and HC (n = 10 – 7 – 10 – 10) CD4+ T cells, measured by ELISA as in (a) and 
normalized to DMSO control (=100%). Statistical analysis: mean ± SEM, repeated measures 1-way ANOVA 
followed by Dunnett’s method for multiple comparisons (a) and 2-way ANOVA (b) followed by Bonferroni’s 
method for multiple comparisons.
Figure 2. JAK inhibitors work on “type 17” cytokine production in-vitro in Spondyloarthritis on established 
peripheral Th17 cells and on synovial fluid CD4+ T cells. (a) Reduction of IL-17A secretion by JAK inhibitors 
(Tofa, JAK3 > JAK1/2; Ruxo, JAK2 > JAK1; Bari, JAK1/2 > TYK2; CEP, JAK2) in AS CD4+ T cells (n = 6), 
primed under Th17-promoting conditions for 6 days, upon restimulation with anti-CD2/3/28 beads for 
24 hours measured by ELISA. (b) Effects of JAK inhibitors on IL-17A secretion (ELISA) from synovial CD4+ T 
cells of SPA patients cultured for 3 days (n = 4, Bari n = 3). Statistical analysis: mean ± SEM, repeated measures 
1-way ANOVA followed by Dunnett’s method for multiple comparisons.
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was equally affected by all inhibitors (Fig. 3b). IL-7-mediated STAT5 phosphorylation was most profoundly 
reduced by Tofa, less so by Bari, Ruxo and CEP (Fig. 3c). GM-CSF induced STAT5 phosphorylation (thought 
to be mediated via JAK2) was not significantly affected by any inhibitor (Fig. 3d). Thus the different inhibitors 
have broad but distinct inhibitory effects on phosphorylation of STAT1, 3 and 5 in our primary patient-derived 
cell-based assays.
siRNA-mediated silencing of JAK1 and 3 and TYK2 inhibits type 17 cytokine responses. In 
order to delineate the roles of the different JAK subtypes on “type 17” cytokine production we next determined 
the effects of siRNA-mediated silencing of JAK 1-3 on Th17 responses in HC CD4+ T cells. We also silenced 
TYK2, as we had no specific TYK2 inhibitor included in our experiments so far. Efficient transfection and 
knock-down in HC CD4+ T cells was confirmed using labelled siRNA, Western Blot, flow cytometry and quan-
titative PCR (qPCR; Supplementary Fig. S4b–e). Targeting JAK1 or JAK3 inhibited IL-17A and IL-17F secretion, 
and JAK3 silencing additionally reduced IL-22 secretion from HC CD4+ T cells cultured under Th17-promoting 
conditions for 3 days in-vitro (Fig. 4a). TYK2 silencing also significantly reduced IL-17A, IL-17F and IL-22 secre-
tion (p = 0.021/0.022/0.021, Fig. 4b), which was confirmed for IL-17A and IL-17F by qPCR (Supplementary 
Fig. S2f). siRNA-mediated silencing of JAK2 had no significant effect in this assay (Fig. 4a). Subsequently we 
examined the effects of siRNA-mediated silencing of JAK1, JAK2 and TYK2 on STAT phosphorylation follow-
ing IL-6 (reported to signal through JAK1/2 – STAT1/3) and IFNα (JAK1/TYK2 - STAT1/5) stimulation of HC 
CD4+ T cells, in order to clarify which JAK was the most promising target to interfere with Th17 maintenance 
and polarization. IFNα (effects thought to be mediated by JAK1/TYK2 and STAT1/5) was used as a surrogate for 
TYK2 specific signaling as IL-23 stimulation required preactivation of human CD4+ T cells for 5 days. Figure 4c 
shows that TYK2 silencing indeed significantly inhibited STAT5 phosphorylation following IFNα stimulation as 
with Tofa treatment (p = 0.003 and 0.042). IL-6-induced phosphorylation of STAT3 was significantly reduced by 
JAK2 silencing (p = 0.002, Fig. 4d). STAT1 phosphorylation upon IL-6 stimulation was significantly reduced by 
JAK1 and JAK2 silencing (p = 0.003 and 0.002, Supplementary Fig. S4h). Combination of JAK1 and JAK2 silenc-
ing showed an additive effect on the phosphorylation of STAT3 and 1 upon IL-6 stimulation.
Figure 3. JAK inhibitors inhibit multiple cytokine-driven STAT phosphorylation events. Inhibition of 
STAT phosphorylation by JAK inhibitors (Tofa, JAK3 > JAK1/2; Ruxo, JAK2 > JAK1; Bari, JAK1/2 > TYK2; 
CEP, JAK2) in freshly isolated AS PBMC (n = 5–6) upon cytokine stimulation assessed by intracellular Flow 
Cytometry. Stimulation with (a) IL-6, (b) IFNα and (c) IL-7 gated on CD4+ T cells and with (d) GM-CSF gated 
on CD14+ Monocytes. Panel on the left shows exemplary flow cytometry plot (light grey filled curves in each 
panel show unstimulated control staining), middle panel shows fold increase of mean fluorescence intensity 
(MFI) compared to unstimulated control and right panel shows frequency of phosphorylated STAT of parental 
population. Statistical analysis: mean ± SEM, 2-way ANOVA followed by Bonferroni’s method for multiple 
comparisons.
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Discussion
We here describe potent in-vitro inhibition of CD4+ T cell production of three important “type 17” cytokines, 
IL-17A, IL-17F and IL-22, using both small molecule JAK inhibitors and siRNA-mediated gene silencing. 
Both approaches were effective for CD4+ T cells derived from patients with Ankylosing Spondylitis, Psoriatic 
Arthritis, Rheumatoid Arthritis as well as healthy controls.
Our data strongly reinforce the concept that compared to recombinant antibodies, which target only one 
or two cytokines at a time, a major advantage of JAK inhibition lies in the simultaneous inhibition of produc-
tion of multiple Th17-related cytokines. As well as inhibiting IL-17F and IL-22, we here show additional inhib-
itory effects on GM-CSF production for Tofacitinib (JAK3 > JAK1/2) and CEP-33779 (JAK2) in AS CD4+ T 
cells. GM-CSF is likely an important pro-inflammatory cytokine in multiple inflammatory diseases including 
AS23–25. The moderate effects of the inhibitors on GM-CSF could possibly be attributed to the fact that GM-CSF 
single-producing lymphocytes may be more resistant to manipulation than other Th cell subsets, and/or that 
GM-CSF/IL-17A double producers contribute only modestly to overall GM-CSF production. Investigation of 
newer and more specific JAK inhibitors with regard to GM-CSF production by Th17 cells seems rational.
Another interesting aspect requiring more detailed investigation is the interference of JAK inhibition with 
“type 17” cytokine secretion from KIR3DL2+ (killer cell immunoglobulin like receptor, three Ig domains and 
long cytoplasmic tail 2) Th17 cells. These cells are enriched in HLA (human leucocyte antigen)-B27-positive SPA 
patients and contain the majority of IL-17A-producing CD4+ T cells6. These cells express higher levels of IL-23 
receptor and upon binding of HLA-B27 heavy chain dimers produce increased amounts of IL-17A. The detailed 
effects of JAK inhibition on this KIR3DL2-B27 heavy chain dimer-induced IL-17A secretion remain to be inves-
tigated in another study.
Our data further suggest that, at least in our assays on primary patient-derived cells, current JAK inhibitors 
are only moderately selective for particular JAK family members and functionally target multiple cytokine path-
ways. One example for this moderate in-vitro selectivity is the fact, that CEP, with claimed 40-fold selectivity 
for JAK2 against JAK1, effectively blocks IFNα signaling in our assays, which is supposed to rely on JAK1 and 
TYK2. On the other hand CEP, as well as the other inhibitors, does not seem to block GM-CSF-induced STAT5 
phosphorylation, which is JAK2-dependent. This could be explained by the fact that monocytes from patients 
with autoimmune disease show sustained STAT5 phosphorylation upon GM-CSF stimulation (greater than 
24 h)26. This phosphorylation was found to be resistant to JAK2/3 inhibition by AG490, another small molecule 
inhibitor of JAK. These data suggest that STAT5 phosphorylation is not purely dependent on kinase activity, 
Figure 4. siRNA-mediated silencing of JAK1 and 3 and TYK2 inhibits “type 17” cytokine responses. (a) 
Reduction of IL-17A, IL-17F and IL-22 secretion (ELISA) upon siRNA-mediated silencing of JAK1/2/3 in HC 
CD4+ T cells cultured under Th17-promoting conditions for 3 days in-vitro. Data shown are normalized on 
cell number at the end of experiment = day 3 (n = 3–7). (b) Reduction of IL-17A, IL-17F and IL-22 secretion 
(ELISA) upon siRNA-mediated silencing of TYK2 in HC CD4+ T cells cultured as in (a). Data shown are 
normalized on mg protein (n = 5/4/3). (c) Inhibition of STAT5 phosphorylation by siRNA-mediated TYK2 
silencing in HC CD4+ T cells upon IFNα stimulation 3 days post transfection compared to Tofa treatment 
(n = 2–5) and (d) of STAT3 phosphorylation by siRNA-mediated JAK1 and JAK2 silencing upon IL-6 
stimulation (n = 1, triplicates). Panel on the left shows exemplary flow cytometry plot (light grey filled curves 
in each panel show unstimulated control staining), middle panel shows fold increase of MFI compared to 
unstimulated control and right panel shows frequency of phosphorylated STAT of parental population. 
Statistical analysis: mean ± SEM, paired t test.
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but could rather depend on mechanisms of dephosphorylation and recycling or degradation. JAK2 silencing 
on the contrary did lower but not significantly reduce IL-17F and IL-22 secretion. This can be explained by the 
smaller number of experiments (n = 3 compared to n = 7 for JAK1) and the relatively small population of IL-23 
receptor-positive CD4+ T cells, in which JAK2 silencing related effects might be overridden by IL-2. The spe-
cific effects of JAK inhibition on IL-23-induced STAT3 phosphorylation could not be examined in this study, 
as there was no robust shift if Il-23 was used on freshly isolated PBMC. This may be because IL-23-mediated 
STAT3 phosphorylation requires preactivation of PBMCs via CD3 and CD28 for 5 days or has to be examined 
in an IL-23 receptor expressing T cell line (e.g. kit225)22,27. IL-6 mediated phosphorylation of STAT3 was only 
modestly affected by small molecule inhibitors of JAK. This seems controversial, as STAT3 phosphorylation is the 
hallmark of IL-6 signaling28. However, it has been shown previously that IL-6 induced STAT1 phosphorylation 
is more sensitive to JAK inhibition than STAT3 phosphorylation and that this effect is dose dependent for Tofa. 
The dose used in our study is lower than the one previously reported to robustly inhibit STAT3 phosphorylation 
in human CD4+ T cells18. The observation that the effect of JAK inhibitors on Th17 cytokine secretion is mainly 
independent of IL-23 in our study could be explained by the relatively low percentage of IL-23R positive cells. 
As IL-2, predominantly signaling through JAK1 and JAK3, can expand established Th17 cells and induce IL-17 
secretion from human PBMC, it is not surprising, that Tofa has a robust inhibitory effect on Th17 cytokine release 
in our assay29. Nevertheless our data showing robust inhibition of multiple Th17 cytokines (IL-17A, IL-17F and 
IL-22) under Th17-promoting conditions strongly support further clinical trials of JAK inhibitors in AS/SPA and 
other Th17-driven inflammatory diseases.
Surprisingly the adverse clinical effects of JAK inhibitors, which are mainly derived from clinical trials and 
from real world experience of Tofacitinib, have been relatively limited even though targeting multiple cytokine 
pathways12. Malignancy and infections are the major adverse effects observed with these inhibitors, but changes 
in lipid and serum transaminase levels, cytopenias, and a reduction of the glomerular filtration rate occur as 
well12. Reactivation of varicella zoster virus is one specific adverse effect of JAK inhibition; however disseminative 
disease is rare30. In regard of JAK selectivity sparing of JAK2 might avoid afore mentioned cytopenias. Reduced 
activity on JAK1 might ameliorate the effect of such inhibitors on antiviral responses, especially through Natural 
Killer cells12. As TYK2 is also involved in IL-10 and type I Interferon signaling, a selective TYK2 inhibitor might 
confer a risk for reduced intrinsic anti-inflammatory function and increased infections12,31. However, reports 
on human TYK2 deficiency show a less severe immunodeficiency phenotype compared to JAK3 deficiency32,33. 
So far safety profiles of JAK inhibitors cannot be accurately derived from the reported in-vitro function of the 
designated JAK. Long term observations and individual clinical trials will have to be undertaken to prove the 
superiority of selective inhibitors.
Although we were not able to test a small molecule inhibitor specific for TYK2, the efficacy of siRNA-mediated 
TYK2 silencing on Th17-associated cytokine secretion supports strategies of TYK2 inhibition for the treatment of 
AS and other Th17-driven diseases (despite the above mentioned caveats and the observed discrepancy for IL-22 
in protein versus messenger RNA level). Recent studies comparing human cell and tissue transcriptomes with 
proteomes have found that agreement between mRNA and protein levels occurs only in about 40%, with differ-
ing translational rates and posttranslational modifications accounting for these differences34. Despite difficulties 
encountered due to the conserved nature of the kinase domain, selective TYK2 inhibitors and novel approaches 
targeting the pseudokinase domain show promise35,36. Alternative pathways of targeting TYK2 by inhibitory pep-
tides have also been employed37. Our silencing experiments also suggest that JAK1 and JAK2 might be effective 
targets for interference with Th17 responses. Baricitinib is a moderately JAK1-specific inhibitor that has already 
been approved for RA treatment in the USA and Europe38.
One further advantage of JAK inhibitors in regard to targeting multiple cytokine pathways might be 
an effect on the changes in bone metabolism observed in AS, namely syndesmophyte formation and bony 
ankylosis. Tofacitinib has been reported to inhibit both inflammation and new bone formation in murine 
Spondyloarthritis39. A current clinical trial of Tofacitinib in AS patients provides the first direct evidence that JAK 
inhibition might also ameliorate bone proliferation in humans17.
In summary our in-vitro data using patient-derived cells show effects of JAK inhibition on multiple “type 17” 
inflammatory cytokines in SPA, and strongly support further clinical trials of multiple JAK inhibitors of varying 
specificity in AS/SPA and other Th17-driven inflammatory diseases.
Patients and Methods
Patient samples. Heparinized venous blood (30 mL) was obtained from patients with AS (modified New 
York criteria), patients with PSA (classification of Psoriatric Arthritis criteria (CASPAR)), patients with RA 
(EULAR criteria) and HC with ethical permission (COREC 06/Q1606/139 and Oxfordshire Research Ethics 
Committee B 07/Q1605/35) and upon informed consent. Synovial fluid was obtained with informed consent 
and same ethical approval from Spondyloarthritis patients meeting assessment of spondyloarthritis international 
society (ASAS) criteria for axial spondyloarthritis40. Leukocyte cones were acquired from National Health Service 
Blood and Transplant. All research was performed in accordance with the relevant guidelines and regulations.
Inhibitors. Tofacitinib, Baricitinib, Ruxolitinib, CEP-33779 and Bayer-18 were purchased from Selleckchem, 
CaymanChemical and Synkinase (reconstituted at 50 mM in DMSO and frozen in aliquots) and used at concen-
trations and durations described in Supplementary Table S1 immediately upon thawing.
Cell Purification and Cell culture. Mononuclear cells from peripheral blood (PBMC) or synovial fluid 
(SFMC) were isolated by Ficoll density-gradient centrifugation (Histopaque; Sigma-Aldrich). 5 × 104 negatively 
selected CD4+ T cells (Miltenyi Biotec, >90% purity on average) were cultured under Th17-promoting condi-
tions as described in online Supplementary Material and Methods.
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ELISA. Supernatants were analyzed with ELISA kits (IL-17A, IL-17F, IL-22, IFNγ; ebioscience and GM-CSF; 
BioLegend).
Cell viability and proliferation assessment. CD4+ T cells were labeled with 5 µM CFSE 
(Carboxyfluorescein succinimidyl ester; Molecular Probes) and cultured as above. Anti-Annexin V and 7-AAD 
(7-Aminoactinomycin D; Biolegend) staining was used for viability assessment after three days of in-vitro culture 
as above. Further information available in online Supplementary Material and Methods.
Intracellular Flow Cytometry. Freshly isolated PBMC or CD4+ T cells were stimulated and stained for 
intracellular flow cytometry of STAT and JAK as described in online Supplementary Material and Methods and 
Supplementary Table S2.
Silencing of JAK1, JAK2, JAK3 and TYK2. CD4+ T cells were electroporated with 2 to 5 µM of the respec-
tive siRNA (Eurogentec and ThermoFisher Scientific) using the Neon™ Transfection System (ThermoFisher 
Scientific). See also online Supplementary Material and Methods and Supplementary Table S3.
Statistical analysis. Between-group differences were determined as indicated in the figure legends using 
paired t-Test, repeated measures 1-way and 2-way ANOVA followed by Dunnett’s or Bonferroni’s method for 
multiple comparisons (GraphPad Prism software version 5). P values less than 0.05 were considered statistically 
significant.
Ethics Approval. Oxfordshire Research Ethics Committee REC06/Q1606/139 and 07/Q1605/35.
Data Availability Statement
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
References
 1. Stolwijk, C., van Onna, M., Boonen, A. & van Tubergen, A. The global prevalence of spondyloarthritis: A systematic review and 
meta-regression analysis. Arthritis Care Res (Hoboken), https://doi.org/10.1002/acr.22831 (2015).
 2. Dougados, M. & Baeten, D. Spondyloarthritis. Lancet 377, 2127–2137, https://doi.org/10.1016/S0140-6736(11)60071-8 (2011).
 3. van der Heijde, D. et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, 
randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54, 2136–2146, https://doi.org/10.1002/art.21913 (2006).
 4. van der Heijde, D. et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-
controlled trial (ASSERT). Arthritis Rheum 52, 582–591, https://doi.org/10.1002/art.20852 (2005).
 5. Landewe, R. et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 
24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis 73, 39–47, https://doi.org/10.1136/
annrheumdis-2013-204231 (2014).
 6. Bowness, P. et al. Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis. 
J Immunol 186, 2672–2680, https://doi.org/10.4049/jimmunol.1002653 (2011).
 7. Shen, H., Goodall, J. C. & Hill Gaston, J. S. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and 
rheumatoid arthritis. Arthritis Rheum 60, 1647–1656, https://doi.org/10.1002/art.24568 (2009).
 8. Baeten, D. et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med 373, 2534–2548, https://doi.
org/10.1056/NEJMoa1505066 (2015).
 9. Poddubnyy, D., Hermann, K. G., Callhoff, J., Listing, J. & Sieper, J. Ustekinumab for the treatment of patients with active ankylosing 
spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis 73, 817–823, https://doi.
org/10.1136/annrheumdis-2013-204248 (2014).
 10. Australo-Anglo-American Spondyloarthritis, C. et al. Genome-wide association study of ankylosing spondylitis identifies non-
MHC susceptibility loci. Nat Genet 42, 123–127, https://doi.org/10.1038/ng.513 (2010).
 11. Ghoreschi, K., Laurence, A. & O’Shea, J. J. Janus kinases in immune cell signaling. Immunol Rev 228, 273–287, https://doi.
org/10.1111/j.1600-065X.2008.00754.x (2009).
 12. Winthrop, K. L. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol 13, 234–243, https://doi.
org/10.1038/nrrheum.2017.23 (2017).
 13. Maeshima, K. et al. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-gamma and interleukin-17 
production by human CD4+ T cells. Arthritis Rheum 64, 1790–1798, https://doi.org/10.1002/art.34329 (2012).
 14. Raychaudhuri, S. K., Abria, C. & Raychaudhuri, S. P. Regulatory role of the JAK STAT kinase signalling system on the IL-23/IL-17 
cytokine axis in psoriatic arthritis. Ann Rheum Dis 76, e36, https://doi.org/10.1136/annrheumdis-2016-211046 (2017).
 15. Burmester, G. R. et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with 
an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381, 451–460, https://doi.
org/10.1016/S0140-6736(12)61424-X (2013).
 16. Changelian, P. S. et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302, 875–878, https://doi.
org/10.1126/science.1087061 (2003).
 17. van der Heijde, D. et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, 
dose-ranging study. Ann Rheum Dis 76, 1340–1347, https://doi.org/10.1136/annrheumdis-2016-210322 (2017).
 18. Ghoreschi, K. et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 186, 4234–4243, 
https://doi.org/10.4049/jimmunol.1003668 (2011).
 19. Karaman, M. W. et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26, 127–132, https://doi.org/10.1038/
nbt1358 (2008).
 20. Parham, C. et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, 
IL-23R. J Immunol 168, 5699–5708 (2002).
 21. International Genetics of Ankylosing Spondylitis, C. et al. Identification of multiple risk variants for ankylosing spondylitis through 
high-density genotyping of immune-related loci. Nat Genet 45, 730–738, https://doi.org/10.1038/ng.2667 (2013).
 22. Dendrou, C. A. et al. Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity. Sci Transl Med 8, 363ra149, 
https://doi.org/10.1126/scitranslmed.aag1974 (2016).
 23. Griseri, T., McKenzie, B. S., Schiering, C. & Powrie, F. Dysregulated hematopoietic stem and progenitor cell activity promotes 
interleukin-23-driven chronic intestinal inflammation. Immunity 37, 1116–1129, https://doi.org/10.1016/j.immuni.2012.08.025 
(2012).
www.nature.com/scientificreports/
8Scientific RepoRts |  (2018) 8:15645  | DOI:10.1038/s41598-018-34026-1
 24. El-Behi, M. et al. The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-
CSF. Nat Immunol 12, 568–575, https://doi.org/10.1038/ni.2031 (2011).
 25. Al-Mossawi, M. H. et al. Unique transcriptome signatures and GM-CSF expression in lymphocytes from patients with 
spondyloarthritis. Nat Commun 8, 1510, https://doi.org/10.1038/s41467-017-01771-2 (2017).
 26. Litherland, S. A. et al. Signal transduction activator of transcription 5 (STAT5) dysfunction in autoimmune monocytes and 
macrophages. J Autoimmun 24, 297–310, https://doi.org/10.1016/j.jaut.2005.02.001 (2005).
 27. Lochmatter, C. et al. Integrative Phosphoproteomics Links IL-23R Signaling with Metabolic Adaptation in Lymphocytes. Sci Rep 6, 
24491, https://doi.org/10.1038/srep24491 (2016).
 28. Mathur, A. N. et al. Stat3 and Stat4 direct development of IL-17-secreting Th cells. J Immunol 178, 4901–4907 (2007).
 29. Amadi-Obi, A. et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 
13, 711–718, https://doi.org/10.1038/nm1585 (2007).
 30. Winthrop, K. L. et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol 66, 2675–2684, 
https://doi.org/10.1002/art.38745 (2014).
 31. Velazquez, L., Fellous, M., Stark, G. R. & Pellegrini, S. A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell 
70, 313–322 (1992).
 32. Kreins, A. Y. et al. Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome. J Exp Med 212, 
1641–1662, https://doi.org/10.1084/jem.20140280 (2015).
 33. Schwartz, D. M., Bonelli, M., Gadina, M. & O’Shea, J. J. Type I/II cytokines, JAKs, and new strategies for treating autoimmune 
diseases. Nat Rev Rheumatol 12, 25–36, https://doi.org/10.1038/nrrheum.2015.167 (2016).
 34. Schwanhausser, B. et al. Global quantification of mammalian gene expression control. Nature 473, 337–342, https://doi.org/10.1038/
nature10098 (2011).
 35. Tokarski, J. S. et al. Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization 
of Its Pseudokinase Domain. J Biol Chem 290, 11061–11074, https://doi.org/10.1074/jbc.M114.619502 (2015).
 36. Masse, C. et al. Identification of highly potent and selective Tyk2 inhibitors for the treatment of autoimmune diseases through 
structure-based drug design (THER2P.961). The Journal of Immunology 194, 67.12 (2015).
 37. Works, M. G. et al. Design of a peptide inhibitor of tyrosine kinase 2. Protein Pept Lett 21, 419–425 (2014).
 38. Keystone, E. C. et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate 
response to methotrexate. Ann Rheum Dis 74, 333–340, https://doi.org/10.1136/annrheumdis-2014-206478 (2015).
 39. Lories, R. et al. Tofacitinib Inhibits Inflammation and New Bone Formation in Murine Spondyloarthritis but Does Not Adversely 
Inhibit Normal Human MSC Function. Arthritis Rheumatol 67 (2015).
 40. Rudwaleit, M. et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis 
and for spondyloarthritis in general. Ann Rheum Dis 70, 25–31, https://doi.org/10.1136/ard.2010.133645 (2011).
Acknowledgements
Prof. H. Schulze-Koops provided helpful advice. The research was funded by Deutsche Forschungsgemeinschaft 
(HA-7021/1-1, AH), Wellcome Trust (MHA 102288/Z/13/Z), Società Italiana di Reumatologia (DS), the National 
Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC) (PB AR).
Author Contributions
A.H., A.S. and P.B. designed the study. M.H.A.M., D.S., P.B. and K.D. recruited patients. A.H., L.C., J.D.W., A.R. 
and T.S. performed experiments. A.H. and P.B. analyzed data, drafted and finalized the manuscript. All authors 
have read and agreed with the manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-34026-1.
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2018
